Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel
暂无分享,去创建一个
Y. Inoue | Hiromichi Ito | Y. Shigematsu | Y. Ono | A. Oba | Takafumi Sato | Y. Ushida | Tomotaka Kato | Y. Takahashi | Takeshi Suzuki
[1] K. Moon,et al. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment , 2021, Cancer research and treatment.
[2] T. Chen,et al. The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium , 2021, Cancer science.
[3] Shaotao Jiang,et al. Surgery and chemotherapy improve the prognosis of primary hepatic angiosarcoma: A retrospective study based on Propensity score matched survival analysis. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[4] H. Lang,et al. Surgical therapy of primary hepatic angiosarcoma , 2019, BMC Surgery.
[5] X. Ren,et al. Primary hepatic angiosarcoma and potential treatment options , 2014, Journal of gastroenterology and hepatology.
[6] R. Danesi,et al. The pharmacological bases of the antiangiogenic activity of paclitaxel , 2013, Angiogenesis.
[7] Yu-xin Jiang,et al. Contrast-enhanced ultrasound study of primary hepatic angiosarcoma: a pitfall of non-enhancement. , 2012, European journal of radiology.
[8] Qiang Li,et al. Primary hepatic angiosarcoma: A retrospective analysis of 6 cases , 2012, Journal of digestive diseases.
[9] How-Ran Guo,et al. Arsenic, vinyl chloride, viral hepatitis, and hepatic angiosarcoma: A hospital-based study and review of literature in Taiwan , 2011, BMC gastroenterology.
[10] M. Koch,et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. , 2011, Surgery.
[11] Y. N. Park,et al. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Blay,et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Blay,et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. D'Angelica,et al. Management of primary liver sarcomas , 2007, Cancer.
[15] B. Brkljačić,et al. Two cases of lethal complications following ultrasound-guided percutaneous fine-needle biopsy of the liver , 1996, CardioVascular and Interventional Radiology.
[16] F. Boccardo,et al. Secondary breast angiosarcoma: lethal response to anti-angiogenic therapy with paclitaxel chemotherapy. A case report. , 2006, Anticancer research.
[17] P. Canney,et al. Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. , 2006, Breast.
[18] K. Skubitz,et al. Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma , 2005, Cancer.
[19] C. Antonescu,et al. A 14‐Year Retrospective Review of Angiosarcoma: Clinical Characteristics, Prognostic Factors, and Treatment Outcomes with Surgery and Chemotherapy , 2005, Cancer journal.
[20] C. Pestoni,et al. Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.
[21] K. Takehara,et al. Weekly low‐dose docetaxel in the treatment of lung metastases from angiosarcoma of the head , 2005, The British journal of dermatology.
[22] E. Molina,et al. Clinical Manifestations of Primary Hepatic Angiosarcoma , 2003, Digestive Diseases and Sciences.
[23] M. Erkan,et al. Five years and 4 months of recurrence-free survival in hepatic angiosarcoma. , 2003, Journal of hepato-biliary-pancreatic surgery.
[24] D. V. van Thiel,et al. Mesenchymal tumors of the liver. , 2001, Clinics in liver disease.
[25] O. Grandas,et al. Hepatic Angiosarcoma: Long-Term Survival after Complete Surgical Removal , 2000, The American surgeon.
[26] G. Schwartz,et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face , 1999, Cancer.
[27] I. Kleinschmidt,et al. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. , 1997, Occupational and environmental medicine.
[28] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] T. Nakashima,et al. Pathomorphologic characteristics of 102 cases of thorotrast‐related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma , 1988, Cancer.
[30] J. Creech,et al. Clinical and morphologic features of hepatic angiosarcoma in vinyl chloride workers , 1976, Cancer.